Skip to content

Treatment of diabetic foot infection with compound Huangbai liquid

Evidence-based Appraisal Research of Traditional Chinese External Tazi Therapy with Fufang Huangbai Ye to Control Diabetic Foot Ulcer with Drug-resistant Bacteria

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041443
Enrollment
Unknown
Registered
2020-12-26
Start date
2020-12-24
Completion date
Unknown
Last updated
2021-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer

Interventions

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the diagnostic criteria of diabetic foot; 2. Patients with IDSA grade 2; 3. Culture confirmed the bacteriological basis, and the wound was infected by drug-resistant bacteria; 4. Patients with HbA1c = 0.4; 7. Patients with wound area between 1 cm x 1cm and 10 cm x 10cm; 8. Patients who voluntarily participated in the trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to compound Phellodendron solution and silver ion antibacterial dressing; 2. Patients who used antibiotics in any way within one week before treatment; 3. Serious heart, liver and kidney dysfunction, which seriously affect the safety and treatment of the subjects, should be ruled out by the researchers; 4. Patients with foot ulcer caused by venous, tumor, radiation, simple arterial and other non-diabetic reasons. 5. Patients with serum albumin < 25g / L; 6. Patients with hemoglobin < 90g / L; 7. Patients whose platelets are lower than the lower limit of normal value; 8. Subjects with pregnancy or birth planning, or pregnant or lactating women; 9. Patients with cognitive impairment can not give full informed consent; 10. Patients with allergic constitution or known hypersensitivity to the components of test drug and control drug; 11. Patients who participated in other clinical trials in recent one month; 12. According to the judgment of the researcher, the patient was unable to complete the study or comply with the requirements of the study.

Design outcomes

Primary

MeasureTime frame
the proportion of resoluting infection;the time of resoluting infection;

Countries

China

Contacts

Public ContactJu Shang

Dongzhimen Hospital, Beijing University of Chinese Medicine

18801020886@163.com+86 18801020886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026